**Article type:** Original Research Article

**Title:** Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

**Authors:** Sherko Kuemmel¹,², Carlo A. Tondini³, Jacinta Abraham⁴, Zbigniew Nowecki⁵, Bartosz Itrych⁶, Erika Hitre⁷, Bogusława Karaszewska⁸, Alejandro Juárez-Ramiro⁹, Flavia Morales-Vásquez¹⁰, Jose Manuel Pérez García¹¹, Servando Cardona-Huerta¹², Estefania Monturús¹³, Marco Sequi¹⁴,¹⁵, Eleonora Restuccia¹³, Mark Benyunes¹⁶ and Miguel Martín¹⁷

**Author affiliations:**

¹ Breast Unit, Kliniken Essen-Mitte, Essen, Germany

² Clinic for Gynecology with Breast Center, Charité – Universitätsmedizin Berlin, Berlin, Germany

³ Department of Onco-Hematology, ASST Papa Giovanni XXIII, Bergamo, Italy

⁴ Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK

⁵ Klinika Nowotworów Piersi i Chirurgii Rekonstrukcyjnej, Centrum Onkologii-Instytut, Warsaw, Poland

⁶ Department of Oncology, Magodent, Warsaw, Poland

⁷ Department of Medical Oncology and Clinical Pharmacology “B”, National Institute of Oncology, Budapest, Hungary
8 Przychodnia Lekarska KOMED, Konin, Poland
9 Medical Oncology, CME Consultorio de Medicina Especializada, Mexico City, Mexico
10 FUCAM, Instituto Nacional de Cancerología de Mexico, Mexico City, Mexico
11 Medical Oncology Department, Vall d’Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Barcelona, Spain
12 Centro de Cáncer de Mama, Hospital Zambrano-Hellion, Tecnológico de Monterrey, Monterrey, Mexico
13 Global Product Development, F. Hoffmann-La Roche Ltd, Basel, Switzerland
14 Biostatistics, F. Hoffmann-La Roche Ltd, Basel, Switzerland
15 Biostatistics, PAREXEL, Milan, Italy
16 Global Product Development, Genentech, Inc., South San Francisco, CA, USA
17 Instituto de Investigación Sanitaria Gregorio Marañón, CIBERONC, Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain

* Corresponding author: Sherko Kuemmel, MD, PhD

Address: Breast Unit, Kliniken Essen-Mitte, Henricistrasse 92, 45136 Essen, Germany

Telephone: +49-201-174-33001

Email: s.kuemmel@kem-med.com

† Current address: Department of Oncology and Hematology, Central Clinical Hospital MSWiA, Warsaw, Poland (Itrych)
‡ Current address: International Breast Cancer Center (IBCC), Quiron Group, Barcelona, Spain (Pérez García)

§ Current address: CROS Academy, Bologna, Italy (Sequi)

Target journal: Breast Cancer Research and Treatment
### Online Resource 5 – Objective response rate

|                          | H SC + P IV + D IV (n = 336) |
|--------------------------|-------------------------------|
| **ORR, no. (%) [95% CI]**|                               |
| CR                       | 42 (12.5)                     |
| PR                       | 212 (63.1)                    |
| Non-responders, no. (%)  | 27 (8.0)                      |
| PD                       | 17 (5.1)                      |
| Not evaluable            | 1 (0.3)                       |
| Missing                  | 9 (2.7)                       |
| Stable disease, no. (%)  | 55 (16.4)                     |
| CBR                      | 309 (92.0)                    |

*CBR* clinical benefit rate, *CI* confidence interval, *CR* complete response, *D IV* intravenous docetaxel, *H SC* subcutaneous trastuzumab, *ORR* objective response rate, *PD* progressive disease, *P IV* intravenous pertuzumab, *PR* partial response

Data are number of patients (%) [95% CI]